| Q43859527 | A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. |
| Q34373532 | Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents. |
| Q42814993 | Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro |
| Q34464958 | Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. |
| Q36322125 | Development of effective therapies against West Nile virus infection |
| Q44036706 | Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir |
| Q34047338 | Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunodeficiency virus activity of nucleoside reverse transcriptase inhibitors |
| Q42631087 | Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects |
| Q31996846 | Guanosine analogues as anti-herpesvirus agents |
| Q28343742 | Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs |
| Q34379808 | Infections in recipients of kidney transplants |
| Q40551606 | Inhibition of reovirus by mycophenolic acid is associated with the M1 genome segment |
| Q34996888 | Mechanisms of action of mycophenolate mofetil in preventing chronic rejection |
| Q43859530 | Mycophenolate and hepatitis C: salve on a wound or gasoline on a fire? |
| Q35601973 | Mycophenolate in dermatology. |
| Q57839861 | Mycophenolate mofetil and animal models |
| Q36085882 | Mycophenolate mofetil and skin diseases |
| Q40669336 | Mycophenolic acid inhibits replication of Type 2 Winnipeg, a cerebrospinal fluid-derived reovirus isolate |
| Q27489893 | Progress on the development of therapeutics against West Nile virus |
| Q40837854 | Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus. |
| Q40820971 | The anti-herpesvirus activity of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl)-cycloprop-1'-yl]methyl]guanine is markedly potentiated by the immunosuppressive agent mycophenolate mofetil. |
| Q44024985 | The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials |
| Q35045949 | Therapy for acute rejection in pediatric organ transplant recipients |
| Q34936164 | Treatment of recurrent hepatitis C. |